Main Menu

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel shipping container designed to protect live cell cultures during transport.

Summary: 

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for clinical validation and to further develop the technology. 

Summary:

The National Cancer Institute (NCI) sees research co-development partners and/or licensees for an automated acoustophoresis device to radio-label and isolate cells.

This technology includes a novel apparatus and method that utilizes Electrochemical Impedance Spectroscopy (EIS) to assess the integrity of epithelial cell membranes non-destructively. By applying frequency-modulated voltage signals and facilitating fluid exchange on both sides of the epithelial tissue, this technology allows researchers to characterize membrane-specific responses with unprecedented accuracy.

Understanding the electrical properties of barrier tissues is crucial for deciphering their physiological functions and pathological conditions. These tissues, such as epithelial and endothelial layers, play critical roles in regulating the transport of ions, nutrients, and signaling molecules. By quantifying membrane-specific resistances, capacitances, and potentials, researchers gain valuable insights into epithelial development, barrier integrity, and disease progression. 

This technology involves the creation of monoclonal antibodies through hybridoma technology, specifically, hybridomas 3B6, 14B7, 2D3, 2G4, 1G3, 6H3, 6C5, and 3D12, which exhibit a high degree of reactivity with Bacillus anthracis protective antigen (PA). These monoclonal antibodies have shown great promise in the field of anthrax detection and diagnosis. Their exceptional specificity for Bacillus anthracis PA suggests their potential application in diagnostic devices.

The groundbreaking technology of high-frequency cell mechanics assessment represents a paradigm shift in the field of cell analysis. This innovation enables rapid and non-invasive evaluation of cell health and viability, eliminating the need for cell labeling or modification. By measuring cell viscoelastic properties at high frequencies, it offers real-time insights into the mechanical characteristics of individual cells and entire populations.

This technology includes the NeurEx® mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app's robust design enables precise mapping of neurological deficits, blending spatial distribution with quantitative assessments.

The technology pertains to a novel polymer nanoparticle platform designed for the creation of individualized cancer vaccines. It utilizes a two-component system that combines patient-specific peptide neoantigens with immunostimulants within self-assembling nanoparticles. This approach ensures the targeted delivery of neoantigens to the immune system, enhancing the immune response against cancer cells while avoiding the systemic activation often seen with conventional adjuvants.

This technology includes a real-time RT-PCR (reverse transcriptase – polymerase chain reaction) Taqman assay using primers and probes specific for EV-D68 viral protein 1 nucleic acid. This assay provides a more specific identification of EV-D68 strains allowing better diagnosis. Human Enterovirus D68 (EV-D68) is a non-polio enterovirus that can cause mild to severe respiratory illness, especially in infants and children with asthma. The assay is simple, validated, and allows rapid testing and detection of EV-D68 in respiratory samples.